Human Volunteers
Conditions
Brief summary
This is a first in human, phase I, open label study of the MVA viral vector (produced in the novel immortalised duck retinal cell line AGE1.CR.pIX) expressing the influenza antigens NP and M1 as a fusion protein, in healthy adult volunteers. MVA-NP+M1 will be given alone intramuscularly as a single dose. There will be 1 study group and a total of 6 volunteers will be enrolled. Staggered enrollment will apply for the first three volunteers within the group.
Interventions
BIOLOGICALMVA-NP+M1
Intramuscular injection of novel vaccine
Sponsors
University of Oxford
Barinthus Biotherapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adults aged 18-50 2. Able and willing (in the Investigator's opinion) to comply with all study requirements 3. Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner 4. For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination (for women of child bearing potential only) 5. Agreement to refrain from blood donation during the course of the study 6. Provide written informed consent
Exclusion criteria
1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period 2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data. 3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate 4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed) 5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine 6. Any history of anaphylaxis in relation to vaccination 7. Pregnancy, lactation or willingness/intention to become pregnant during the study (for women of child bearing potential only) 8. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) 9. History of serious psychiatric condition likely to affect participation in the study 10. Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture 11. Any other serious chronic illness requiring hospital specialist supervision 12. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week 13. Suspected or known injecting drug abuse in the 5 years preceding enrolment 14. Seropositive for hepatitis B surface antigen (HBsAg) 15. Seropositive for hepatitis C virus (antibodies to HCV) 16. Any clinically significant abnormal finding on screening biochemistry and haematology blood tests or urinalysis 17. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data 18. Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure of local reactogenicity following intramuscular injection of MVA-NP+M1 | 7 days post vaccination | Occurrence and severity of solicited local reactogenicity signs and symptoms for 7 days following vaccination using a diary card. |
| Measure of systemic reactogenicity following intramuscular injection of MVA-NP+M1 | 7 days post vaccination | Occurrence and severity rating of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination using a diary card. |
| Measure the occurrence of adverse events following intramuscular injection of MVA-NP+M1 | 28 days post vaccination | Occurrence and severity of unsolicited adverse events for 28 days following the vaccination using a diary card. |
| Assessment of safety laboratory assessments following intramuscular injection of MVA-NP+M1 | 28 days post vaccination | Review of changes in safety laboratory measures from baseline visit to Day 2, Day 7, Day 21 and Day 28 visits |
| Serious Adverse Events that occur during the study | 28 days post vaccination | Review of causality and relationship to MVA-NP+M1 for any serious adverse events during the whole study duration |
Countries
United Kingdom
Outcome results
None listed